Tracon Pharmaceuticals Inc (TCON)
$1.27
Insights on Tracon Pharmaceuticals Inc
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 235.1% return, outperforming this stock by 313.6%
Performance
- $1.24$1.38$1.27
2.36%
Downside
Day's Volatility :10.14%
Upside
7.97%
- $1.21$14.75$1.27
4.72%
Downside
52 Weeks Volatility :91.8%
Upside
91.39%
Returns
| Period | Tracon Pharmaceuticals Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -66.31% | 0.0% |
6 Months | 525.62% | 0.0% |
1 Year | 113.73% | 0.0% |
3 Years | -78.47% | -22.6% |
Highlights
Market Capitalization | 3.5M |
Book Value | - $0.36 |
Earnings Per Share (EPS) | 107.23 |
PE Ratio | 0.01 |
PEG Ratio | 0.0 |
Wall Street Target Price | 30.5 |
Profit Margin | -29.79% |
Operating Margin TTM | 13.37% |
Return On Assets TTM | -29.16% |
Return On Equity TTM | -1277.01% |
Revenue TTM | 12.0M |
Revenue Per Share TTM | 7.36 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | -13.9M |
EBITDA | -6.9M |
Diluted Eps TTM | 107.23 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -4.17 |
EPS Estimate Next Year | -2.86 |
EPS Estimate Current Quarter | -1.19 |
EPS Estimate Next Quarter | -1.09 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 2301.57%
Technicals Summary
Sell
Neutral
Buy
Tracon Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Tracon Pharmaceuticals Inc | -29.83% | 525.62% | 113.73% | -78.47% | -80.34% |
 Moderna, Inc. | 21.03% | 85.08% | 14.68% | -28.27% | 659.22% |
 Regeneron Pharmaceuticals, Inc. | 3.22% | 20.18% | 31.88% | 93.3% | 227.58% |
 Novo Nordisk A/s | 8.85% | 34.38% | 71.83% | 235.07% | 463.44% |
 Vertex Pharmaceuticals Incorporated | 16.81% | 34.1% | 40.6% | 123.97% | 174.53% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Tracon Pharmaceuticals Inc | 0.01 | 0.01 | 0.0 | -4.17 | -12.77 | -0.29 | NA | -0.36 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.14 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 28.89 | 28.89 | 1.46 | 44.13 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 46.97 | 46.97 | 2.36 | 3.5 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 29.59 | 29.59 | 0.53 | 17.08 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Tracon Pharmaceuticals Inc | Buy | $3.5M | -80.34% | 0.01 | -29.79% |
Moderna, Inc. | Buy | $54.6B | 659.22% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $108.0B | 227.58% | 28.89 | 29.45% |
Novo Nordisk A/s | Buy | $602.6B | 463.44% | 46.97 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $117.5B | 174.53% | 29.59 | 39.46% |
Institutional Holdings
Acadian Asset Management LLC
0.77%Squarepoint Ops LLC
0.77%Vanguard Group Inc
0.49%BlackRock Inc
0.49%BOOTHBAY FUND MANAGEMENT, LLC
0.48%Geode Capital Management, LLC
0.39%
Company Information
tracon pharmaceuticals, inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (amd). its lead clinical stage products include envafolimab (kn035), an investigational pd-l1 single-domain antibody for the treatment of soft tissue sarcoma. the company's clinical stage products also include de-122, which is in randomized phase iia study for the treatment of wet amd; trc102, which is a small molecule that is in phase ii clinical trial for the treatment of mesothelioma, phase i clinical trial to treat solid tumors, phase i/ii to treat solid tumors and lymphomas, and phase i trial to treat lung cancer; trc253, a small molecule, which is in a phase ii clinical trial for the treatment of metastatic castration-resistant prostate cancer; and tj004309, a cd73 antibody that is in phase i clinical development for the treatment of solid tumors. it has collaboration and license agreements w
Organization | Tracon Pharmaceuticals Inc |
Employees | 17 |
CEO | Dr. Charles P. Theuer M.D., Ph.D. |
Industry | Health Technology |
Discover More
A Spac I Acquisition Corp
$1.27
-0.78%
Keyarch Acquisition Corp
$1.27
-0.78%
Connexa Sports Technologies Inc
$1.27
-0.78%
Us Value Etf
$1.27
-0.78%
First Wave Biopharma Inc
$1.27
-0.78%
Global X Msci Next Emerging
$1.27
-0.78%
Fat Projects Acquisition Corp
$1.27
-0.78%
Goal Acquisitions Corp
$1.27
-0.78%
Capital Link Global Fintech
$1.27
-0.78%